Cero Therapeutics Faces Nasdaq Delisting Notice
Ticker: CEROW · Form: 8-K · Filed: Jun 13, 2025 · CIK: 1870404
Sentiment: bearish
Topics: delisting, listing-standards, compliance
Related Tickers: CERO
TL;DR
Nasdaq's kicking Cero out, they're fighting back with a hearing.
AI Summary
Cero Therapeutics Holdings, Inc. announced on June 11, 2025, that it received a notice from Nasdaq regarding its failure to meet continued listing requirements. The company is currently evaluating its options and plans to request a hearing with the Nasdaq Hearings Department.
Why It Matters
This notice indicates potential delisting from Nasdaq, which could significantly impact the company's stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — The company has received a notice of delisting from Nasdaq, posing a significant risk to its continued public trading.
Key Players & Entities
- Cero Therapeutics Holdings, Inc. (company) — Registrant
- Nasdaq (company) — Listing Exchange
- June 11, 2025 (date) — Date of earliest event reported
FAQ
What specific continued listing requirements did Cero Therapeutics fail to meet?
The filing states that Cero Therapeutics received a notice from Nasdaq indicating a failure to meet continued listing requirements, but does not specify which requirements were not met.
What is Cero Therapeutics' plan in response to the delisting notice?
Cero Therapeutics plans to evaluate its options and request a hearing with the Nasdaq Hearings Department to present its plan to regain compliance.
When did Cero Therapeutics receive this notice from Nasdaq?
The earliest event reported in the filing is dated June 11, 2025, which is when the notice was received.
What is the former name of Cero Therapeutics Holdings, Inc.?
The former name of Cero Therapeutics Holdings, Inc. was Phoenix Biotech Acquisition Corp., with a name change date of June 30, 2021.
Where is Cero Therapeutics Holdings, Inc. incorporated and what is its business address?
Cero Therapeutics Holdings, Inc. is incorporated in Delaware and its business address is 201 Haskins Way, Suite 230, South San Francisco, CA 94080.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 13, 2025 regarding CERO THERAPEUTICS HOLDINGS, INC. (CEROW).